Neuren Pharmaceuticals (ASX:NEU) has announced the addition of SYNGAP1-related disorder to the development pipeline for its investigational therapy NNZ-2591, marking another step in the company’s strategy to target rare, genetically defined neurodevelopmental disorders. …
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 Australian Biotech
Latest Video
New Stories
-
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News